Shanghai Junshi Biosciences Files HKEX Next Day Return Disclosing Share Buyback for CancellationPUBT·Nov 18, 2026 at 09:35 AM01877-1.35%688180+0.08%
Shanghai Junshi Biosciences Files HKEX Next-Day Return on Share Buyback for CancellationPUBT·Nov 17, 2026 at 09:55 AM01877-1.35%
Weekly Recap | JUNSHI BIO +1.95%, consensus target above spotWeekly Review·Nov 7, 2026 at 09:41 AM01877-1.35%
Shanghai Junshi Biosciences Co., Ltd. Class H (1877) Gets a Buy from CICCTip Ranks·Nov 5, 2026 at 05:05 AM01877-1.35%688180+0.08%
Shanghai Junshi Biosciences Plans to Invest Up to RMB 2 Billion in Idle Proceeds in Principal-Guaranteed ProductsPUBT·Oct 29, 2026 at 01:46 PM01877-1.35%688180+0.08%
Junshi Biosciences Doses First Patient in Phase 3 Trial of JS207-JS007 for Advanced Liver CancerPUBT·Oct 29, 2026 at 11:21 AM01877-1.35%688180+0.08%
China Grants Regular Approval to Junshi Biosciences’ Toripalimab for Previously Treated Urothelial CancerPUBT·Oct 28, 2026 at 01:50 PM01877-1.35%688180+0.08%
Hong Kong's Niche Stocks Forge New Paths: Junshi's Lung Cancer Breakthrough, Noah's AI Wealth ShiftGlobal Report·Oct 28, 2026 at 09:20 AM09889-1.12%01877-1.35%
Junshi Biosciences' Toripalimab Plus Chemotherapy Cuts Death Risk 34% in Phase 3 Lung Cancer TrialPUBT·Oct 28, 2026 at 03:48 AM01877-1.35%688180+0.08%